Lutetium-177-PSMA-617: A Vision of the Future

Elias Chandran, William D. Figg*, Ravi Madan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

In the last decade, many life-prolonging therapeutic options have emerged for metastatic castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[177Lu]Lu-PSMA-617 in post-chemotherapy mCRPC. This journal club reviews the VISION trial in the context of the earlier TheraP trial of [177Lu]Lu-PSMA-617 in mCRPC post docetaxel and androgen pathway inhibition, to provide direction for the real-world application of [177Lu]Lu-PSMA-617. Treatment in the control groups differed significantly between both trials and may have influenced outcomes: TheraP mandated cabazitaxel whereas VISION’s design could not allow it. In both trials, [177Lu]Lu-PSMA-617 had a good safety profile, with common adverse events being fatigue, nausea, dry mouth, marrow suppression and diarrhea. Given its efficacy and favorable safety even in heavily pre-treated patients, [177Lu]Lu-PSMA-617 provides hope to mCRPC patients and may be applied to earlier disease stages in future investigations.

Original languageEnglish
Pages (from-to)186-190
Number of pages5
JournalCancer Biology and Therapy
Volume23
Issue number1
DOIs
StatePublished - 2022
Externally publishedYes

Keywords

  • FDG PET-CT
  • PSMA
  • Prostate cancer
  • cabazitaxel
  • lutetium
  • mCRPC
  • radioligand therapy

Fingerprint

Dive into the research topics of 'Lutetium-177-PSMA-617: A Vision of the Future'. Together they form a unique fingerprint.

Cite this